Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by North Star Asset Management Inc.

North Star Asset Management Inc. cut its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 2.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 225,363 shares of the company's stock after selling 6,058 shares during the quarter. North Star Asset Management Inc. owned approximately 0.45% of Prestige Consumer Healthcare worth $17,599,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PBH. Kestra Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth approximately $27,000. CIBC Private Wealth Group LLC boosted its holdings in Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares during the period. Headlands Technologies LLC bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth about $40,000. McIlrath & Eck LLC boosted its stake in shares of Prestige Consumer Healthcare by 19.1% in the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after acquiring an additional 154 shares during the period. Finally, Johnson Financial Group Inc. bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth about $93,000. 99.95% of the stock is currently owned by institutional investors.

Insider Activity at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares of the company's stock, valued at $1,544,130. The trade was a 8.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Stock Down 0.2%

NYSE:PBH traded down $0.14 during mid-day trading on Thursday, hitting $84.21. 81,887 shares of the company's stock traded hands, compared to its average volume of 297,361. The company has a fifty day moving average of $83.60 and a 200 day moving average of $82.38. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The company has a market capitalization of $4.16 billion, a P/E ratio of 19.75, a P/E/G ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a twelve month low of $62.35 and a twelve month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. The firm had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The business's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.02 earnings per share. On average, analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on PBH shares. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Canaccord Genuity Group upped their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Oppenheimer increased their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. Royal Bank of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Finally, DA Davidson raised their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.